Tivic Health Systems Inc

Valion Bio, Inc. is a late-stage immunotherapeutics company. Its lead drug candidate, Entolimod, is a TLR5 agonist in late-stage development for acute radiation syndrome. The pipeline also includes Entolimod for neutropenia and lymphocyte exhaustion, and Entolasta, an immunologically optimized variant of Entolimod for chronic applications. The company also offers CDMO services. It was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. Incorporated in 2016, it is based in San Antonio, Texas.